Submission Details
| 510(k) Number | K160090 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | January 15, 2016 |
| Decision Date | May 16, 2016 |
| Days to Decision | 122 days |
| Submission Type | Traditional |
| Review Panel | Immunology (IM) |
| Summary | Summary PDF |
K160090 is an FDA 510(k) clearance for the Lumipulse G ROMA, a Ovarian Adnexal Mass Assessment Score Test System (Class II — Special Controls, product code ONX), submitted by Fujirebio Diagnostics,Inc. (Malvern, US). The FDA issued a Cleared decision on May 16, 2016, 122 days after receiving the submission on January 15, 2016. This device falls under the Immunology review panel. Regulated under 21 CFR 866.6050.
| 510(k) Number | K160090 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | January 15, 2016 |
| Decision Date | May 16, 2016 |
| Days to Decision | 122 days |
| Submission Type | Traditional |
| Review Panel | Immunology (IM) |
| Summary | Summary PDF |
| Product Code | ONX — Ovarian Adnexal Mass Assessment Score Test System |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.6050 |
| Definition | An Ovarian/adnexal Mass Assessment Test Is A Devicem That Measures One Or More Proteins In Serum. It Yields A Single Result For The Likelihood That An Adnexal Pelvic Mass In A Woman, For Whom Surgery Is Planned, Is Malignant. The Test Isn For Adjunctive Use, In Teh Context Of A Negative Primary Clinical And Radiological Evaluation, To Augmrent The Identification Of Patienets Whose Gynecologic Surgery Requires Oncology Expertise And Resources. |